<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04174625</url>
  </required_header>
  <id_info>
    <org_study_id>DRGS-2014-2015-165-5</org_study_id>
    <nct_id>NCT04174625</nct_id>
  </id_info>
  <brief_title>The Effect of Omega 3 on 25 Hydroxyvitamin D</brief_title>
  <acronym>n-3FAon25OHD</acronym>
  <official_title>The Effect of Omega 3 Supplementations on Serum 25 Hydroxyvitamin D Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Applied Science Private University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Applied Science Private University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of omega 3 fatty acid on serum 25-hydroxyvitamin D levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No data are available on the effect of omega 3 on serum 25-hydroxyvitamin D levels in
      Jordanian men and women.

      This study was designed to investigate whether omega 3 supplementation has a potential effect
      on the reducing of serum 25-hydroxyvitamin D levels.

      This randomized, placebo-controlled clinical trial (RCT) was designed to evaluate 300 mg
      omega-3FA daily for 2 months on serum levels of 25-hydroxyvitamin D levels. This RCT will be
      conducted on 80 to 90 Jordanian men and women aged 22 to 66 years. Baseline and follow-up
      levels for 25-hydroxyvitamin D (25OHD), parathyroid hormone (PTH), calcium, phosphate, liver
      and kidney functions will be assayed.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 25, 2019</start_date>
  <completion_date type="Anticipated">December 15, 2020</completion_date>
  <primary_completion_date type="Actual">July 8, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum concentrations of 25-hydroxyvitamin D</measure>
    <time_frame>8 weeks</time_frame>
    <description>ng/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum concentrations of PTH</measure>
    <time_frame>8 weeks</time_frame>
    <description>pg/mL</description>
  </primary_outcome>
  <other_outcome>
    <measure>serum concentration of calcium</measure>
    <time_frame>8 weeks</time_frame>
    <description>mg/dl</description>
  </other_outcome>
  <other_outcome>
    <measure>serum concentration of phosphate</measure>
    <time_frame>8 weeks</time_frame>
    <description>mg/dl</description>
  </other_outcome>
  <other_outcome>
    <measure>serum ALT</measure>
    <time_frame>8 weeks</time_frame>
    <description>U/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum urea</measure>
    <time_frame>8 weeks</time_frame>
    <description>mg/dL</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>25-hydroxyvitamin D Levels</condition>
  <arm_group>
    <arm_group_label>Omega3-FA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omega3-FA group 1000 mg wild salmon and fish oil complex (contains 300 mg of omega3-FA) once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VD3 group 50,000 IU/week</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary Supplement: Omega3-FA</intervention_name>
    <description>Dietary Supplement: Omega3-FA 300 mg of omega3-FA once daily for 8 weeks</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Omega3-FA group</arm_group_label>
    <other_name>n-3FA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age â‰¥18 years old

        Male and female Jordanian ASU students and employees who live in Amman.

        Informed written consent from the participant prior to the start of the study.

        a serum 25(OH)D concentration between 10 and 70 ng/mL.

        Exclusion Criteria:

        Any eligiable subject refuses to apply with informed written consent before the start of
        the study.

        Men or women previously diagnosed with chronic diseases, including kidney disease or GIT
        problems.

        Who are receiving vitamin D3 supplements (3 months before the start of the study) .

        Pregnants,Breastfeeding females ,Females using hormonal contraceptives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmoud S Abu-Samak, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacy and Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mahmoud S Abu-Samak</name>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Applied Science Private University</investigator_affiliation>
    <investigator_full_name>Mahmoud Suleiman Abu-Samak</investigator_full_name>
    <investigator_title>Prof.Dr. Mahmoud Suleiman Abu-Samak</investigator_title>
  </responsible_party>
  <keyword>omega 3</keyword>
  <keyword>25 hydroxyvitamin D</keyword>
  <keyword>25OHD</keyword>
  <keyword>Vitamin D</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>after six months</ipd_time_frame>
    <ipd_access_criteria>open access</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

